HKUBio teams up with CUHK Medical School and HKSTP to spotlight Hong Kong’s life and health breakthroughs at the BIO International Convention

HKUBio, in collaboration with InvestHK, joined HKSTP as one of 16 prominent life and health technology companies showcasing at BIO 2025 in Boston, USA.

HKUBio, a spin-off of HKU’s LKS Faculty of Medicine, joined Hong Kong’s landmark delegation to BIO 2025 in Boston—one of the world’s largest biotech events.

In collaboration with HKSTP, CUHK Faculty of Medicine, and InvestHK, the team spotlighted Hong Kong’s breakthroughs in diagnostics, therapeutics, and medtech innovation. Representing HKU’s cutting-edge research and commercialization efforts, HKUBio was part of a cohort of 16 health tech companies, many from HKSTP’s Incu-Bio and ELITE programmes.

Highlights included Immuno Cure’s partnership for needle-free HIV vaccine delivery and ARBELE, an HKUMed-affiliated spin-off, winning the Biomedical Pitch Competition. The delegation attracted global investors and partners, reinforcing HKUBio’s role in advancing life sciences excellence.

With support from the HKSAR Government and ties to renowned institutions like MIT and Harvard, HKUBio continues to elevate Hong Kong’s position as a global biotech innovation hub.